FindTrial
Sign In

Use of nalbuphine, dexmedetomidine and tramadol for treatment of post-spinal shivering after Caesarean section.

Comparison of efficacy and safety of nalbuphine, dexmedetomidine and tramadol for treatment of post-spinal shivering in pregnant women undergoing Caesarean section

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/07/034963
Enrollment
80
Registered
2021-07-19
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O754- Other complications of obstetric surgery and procedures

Interventions

Intervention1: nalbuphine group: nalbuphine 0.06mg/kg for shivering Control Intervention1: dexmedetomidine group: dexmedetomidine 0.04 microg/kg for shivering Control Intervention2: tramadol: tramadol

Sponsors

Government Institute of Medical sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients from obstetrics group aged between 20â??40 years of ASA grade I and II undergoing caesarean section.2. Patients who will give a valid informed written consent. 3.Patients who will develop shivering of grade 3or4.

Exclusion criteria

Exclusion criteria: 1. Patients of age group between 20-40belonging to ASA grade III and IV. 2. Patients with known hypersensitivity to tramadol, dexmedetomidine and nalbuphine. 3. Patients who will not give valid informed consent. 4. Patients who will have shivering before spinal anaesthesia. 5. Patients who will have shivering before delivery. 6. Contraindication of spinal anaesthesia.

Design outcomes

Primary

MeasureTime frame
To clinically compare the efficacy of either of three drugs to effectively abolish post spinal shivering.Timepoint: 0,5, 10, 15, 30 min, 60 min—

Secondary

MeasureTime frame
To assess â?¢Hemodynamic effects â?¢Sedation â?¢Side effectsTimepoint: 0,5, 10, 15, 30 min, 60 min—

Countries

India

Contacts

Public ContactDr Abhishak Kumar Varshney

Gims

nazunazir@gmail.com9560102957

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026